Association of nodular hyperplasiawith resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 6, 2010, Pages 577-582

  Hirai, Takayuki ^a   Nakashima, Ayumu ^a,b   Takasugi, Norihisa ^a   Yorioka, Noriaki ^b  

^a Hakuai Hospital   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cinacalcet; Hemodialysis; Nodular hyperplasia; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CINACALCET; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFECT; ECHOGRAPHY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; NODULAR HYPERPLASIA; ORGAN SIZE; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG RESISTANCE; HYPERPLASIA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

AGED; DRUG RESISTANCE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID GLANDS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 78651495919     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00843.x     Document Type: Article

References (18)

1. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histo-pathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13:78-86.
2. Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007;22:1828-39.
3. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141-52.
4. Tominaga Y, Matsuoka S, Sato T et al. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathroidectomy. Ther Apher Dial 2007;11:266-73.
5. Okuno S, Ishimura E, Kitatani K et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003;18:2613-21.
6. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994;68:221-8.
7. Fukagawa M, Kurokawa K. Pathogenesis and medical treatment of secondary hyperparathyroidism. Semin Surg Oncol 1997;13:73-7.
8. Hirai T, Nakashima A, Takasugi N, Yorioka N. Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size. Nephron Clin Prac 2009;114:187-93.
9. Tanaka M, Nakanishi S, Komaba H, Itoh K, Matsushita K, Fukagawa M. Association between long-term efficacy of cinacalcet and parathyroid gland volume in hemodialysis patients with secondary hyperparathyroidism. NDT Plus 2008;1(suppl 3):iii49-iii53.
10. Japanese Society for Dialysis Therapy. Guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. J Jpn Soc Dial Ther 2006;39:1453-5.
11. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. BMJ 1973;15:643-6.
12. Taniguchi M, Tokumoto M, Tsuruya K, Hirakata H, Iida M. Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant 2008;23: 3662-9.
13. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24:982-9.
14. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005;67:467-76.
15. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598-606.
16. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36.
17. Yano S, Sugimoto T, Tsukamoto T et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000;58:1980-6.
18. Mizobuchi M, Hatamura I, Ogata H et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004;15:2579-87.